News & Events

Probiodrug AG to Publish its Third Quarter 2017 Business Update on 30 November 2017

HALLE (SAALE), Germany, 23 November 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its […]

Probiodrug to Present Data from its Phase 2a SAPHIR Study at International Alzheimer’s Disease Conference

Prof. Philipp Scheltens, Principal Investigator of the study, to present at Clinical Trials on Alzheimer’s Disease (CTAD) 2017 in Boston   Management will host a conference […]

Probiodrug to present at Life Sciences Conferences in November

HALLE (SAALE), Germany, 24 October 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]

Probiodrug initiates Phase 2b core program of PQ912 and details further strategy

Company moves seamlessly from finalization of the SAPHIR Phase 2a to next clinical stage Probiodrug takes a double-pronged strategy – starts operational preparation of clinical studies […]

Probiodrug to present at Life Sciences Conferences in October 2017

HALLE (SAALE), Germany, 28 September 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]

Probiodrug reports financial results for H1 2017 and corporate update

PQ912 delivers positive pharmacodynamic and efficacy results in a Phase-2a study  in early stage AD patients Successful settlement of longpending tax issue PQ912 demonstrates efficacy in […]

Probiodrug to present and attend at International Conferences in September 2017

HALLE (SAALE), Germany, 30 August 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]

Unique binding mode of PBD-C06 to pGlu-Abeta peptides identified

Probiodrug publishes mechanism of target binding for its lead anti-pGlu-Abeta monoclonal antibody PBD-C06     HALLE (SAALE), Germany, 29 August 2017 – Probiodrug AG (Euronext Amsterdam: PBD), […]

Probiodrug AG to Publish First Half 2017 Results on 31 August 2017

HALLE (SAALE), Germany, 24 August 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its results […]